Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 1997

View Archived Issues

Synthetic retinoids with anticoagulant effects

SDZ-MRL-953 prevents sepsis in cancer patients

Preclinical profile of Ono-1101 published

SciClone issued European patent for use of thymosin alpha 1 for hepatitis C

Matrix discontinues U.S. development of AccuSite

Biomira reports phase II results for cancer vaccine

Preclinical studies show broad antiseizure properties of ganaxolone

Oncologic Drugs Advisory Committee meets this week

LG Chemical licenses thrombin inhibitor to Warner-Lambert

NC-1800 now in phase II development

Chugai accelerates R&D outside Japan

Pharmacological characterization of BIBU-52

Kirin's TPO enters phase II in several Asian countries

Kyowa Hakko antiparkinsonian enters phase II trials

Amphetamines may provide long-term benefit in patients with ADHD

MIT licenses drug discovery technology to Dyax

Benefits of magnesium sulfate investigated in patients with unstable angina

Cytel and Searle to collaborate on cancer therapies

Myocardial and cerebral vasodilating effects of BMS-180448 in animals

Molecumetics and Teijin begin oral thrombin inhibitor collaboration

Potent GH secretagogues synthesized at Merck & Co.

Gene Logic and Japan Tobacco enter genomic alliance

Novel antibacterial agents from R.W. Johnson

Novartis evaluates SDZ-267-489 and analogues for increasing HDL cholesterol

Cardiovascular effects of SB-209509 and sumatriptan compared in dogs

Hormone therapy vs. simvastatin for hypercholesterolemia in postmenopausal women

Novel neuroprotective agent developed at Takeda

Mitsubishi describes synthesis and activity of MKC-242

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...